CompletedNot Applicable

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

Egypt20 participantsStarted 2024-06-09

Plain-language summary

The aim of this study is to evaluate the efficacy and safety of intraocular methotrexate (MTX) in preventing and managing proliferative vitreoretinopathy (PVR) in patients undergoing retinal detachment surgery

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 years and older. * Diagnosed with RRD with clinical signs of PVR. * No history of prior ocular surgeries for RRD or PVR. Exclusion Criteria: * Patients with other retinal diseases (e.g., diabetic retinopathy or retinal vascular occlusions). * Individuals with significant systemic illnesses that could influence surgical outcomes.

What they're measuring

Visual Acuity

Timeframe: 3 and 6 months after tamponade removal

Anatomical Success

Timeframe: within 6 months after tamponade removal

Number of Operations Required

Timeframe: within 6 months after tamponade removal

Trial details

NCT IDNCT07058337

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Retinal Detachment trials